Soy isoflavone supplementation for breast cancer risk reduction: a randomized phase II trial.

Department of Surgery, Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago IL 60611, USA.
Cancer Prevention Research (Impact Factor: 5.27). 02/2012; 5(2):309-19. DOI: 10.1158/1940-6207.CAPR-11-0251
Source: PubMed

ABSTRACT Soy isoflavone consumption may protect against breast cancer development. We conducted a phase IIB trial of soy isoflavone supplementation to examine its effect on breast epithelial proliferation and other biomarkers in the healthy high-risk breast. One hundred and twenty-six consented women underwent a random fine-needle aspiration (rFNA); those with 4,000 or more epithelial cells were randomized to a double-blind 6-month intervention of mixed soy isoflavones (PTIG-2535) or placebo, followed by repeat rFNA. Cells were examined for Ki-67 labeling index and atypia. Expression of 28 genes related to proliferation, apoptosis, and estrogenic effect was measured using quantitative reverse transcriptase PCR. Hormone and protein levels were measured in nipple aspirate fluid (NAF). All statistical tests were two-sided. Ninety-eight women were evaluable for Ki-67 labeling index. In 49 treated women, the median Ki-67 labeling index was 1.18 at entry and 1.12 post intervention, whereas in 49 placebo subjects, it was 0.97 and 0.92 (P for between-group change: 0.32). Menopausal stratification yielded similar results between groups, but within premenopausal soy-treated women, Ki-67 labeling index increased from 1.71 to 2.18 (P = 0.04). We saw no treatment effect on cytologic atypia or NAF parameters. There were significant increases in the expression of 14 of 28 genes within the soy, but not the control group, without significant between-group differences. Plasma genistein values showed excellent compliance. A 6-month intervention of mixed soy isoflavones in healthy, high-risk adult Western women did not reduce breast epithelial proliferation, suggesting a lack of efficacy for breast cancer prevention and a possible adverse effect in premenopausal women.

1 Follower
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Background and aim of the work: Antioxidants can reduce damage produced by low doses of radiation on living cells. This study was designed to investigate the effects of fermented soy milk (FSM) and low dose of gamma radiation on carcinogenic effect of N-methyl-N-nitrosourea (MNU). Material and methods: Female rats were divided into 8 groups: group (1): control, group (2): injected with MNU, group (3): whole body exposed to low dose of gamma radiation (0.5 Gy), group (4): given FSM orally, group(5): given FSM and MNU, group (6): received MNU and exposed to gamma radiation,, group (7): given FSM, MNU and exposed to gamma radiation. Results: Fermented soy milk exerted significant, ameliorative effect on glutathione peroxidase, superoxide dismutase and catalase activities, lipid peroxidation and TNF-α levelin rats injected with MNU. Combined treatment of FSM and low dose of gamma radiation markedly elevated GSH level, ameliorated MNU effect on cell cycle phases Go/1, S, G2/M and induce apoptosis via activation of caspase-3.Conclusion: FSM consumption with exposure to low doses of gamma radiation reduced carcinogenesis and oxidative stress effects induced by MNU in the mammary tissues.
    Nature and Science of Sleep 01/2013; 11(11):35-42.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The societies of the world in the 21(st) century have faced challenges arising from an aging population as the fertility rate has dropped dramatically and medical advances have extended the average human life span. The elderly aged 65 years or older make up at least 20% of the population in Korea, making the country a super-aging society as defined by the United Nations. The number of elderly women is higher than that of elderly men and women live longer than men. Based on the analysis of recent trends in previous studies, this study aimed to suggest practical strategies to utilize isoflavones, substances chemically similar to the female hormone estrogen, and to search for effective anti-aging strategies using this substance for women to be prepared to reach the elderly stage in good health.
    12/2014; 20(3):85-9. DOI:10.6118/jmm.2014.20.3.85
  • [Show abstract] [Hide abstract]
    ABSTRACT: Genistein is a widely consumed phytoestrogen in dietary supplements and has been reported to play roles in both cancer prevention and promotion. These conflicting effects may be complicated by sex differences. Cytochrome P450 1A (CYP1A) participates in carcinogen activation and detoxification, and the enzyme may interact with genistein. Therefore, modulation of CYP1A by a combination of genistein and sex hormones could be responsible for sex differences related to cancer prevention and promotion. In the current study, a human liver cell line, HepG2/C3A, cultured in sex hormone-supplemented media was used to investigate the modulatory effect of genistein on CYP1A gene expression and activity. Genistein exerted both long-term (72 h) induction and short-term (immediate) inhibition of CYP1A activity in HepG2/C3A cells. In the long-term study, CYP1A gene expression and enzyme activity were induced to a greater extent in male hormone-supplemented cells than female ones. In the short-term study, CYP1A activity was inhibited more strongly by genistein in the male hormone-supplemented cells than in the female hormone-supplemented cells. These significant differences suggest that male hormones can modulate the effects of genistein on CYP1A gene expression and activity.
    In Vitro Cellular & Developmental Biology - Animal 12/2014; 51(4). DOI:10.1007/s11626-014-9848-9 · 1.00 Impact Factor

Full-text (2 Sources)

Available from
May 19, 2014